Drug
Rasagiline clinical trials
Also written Azilect and TVP-1012.
- studies test it
- 50
- open now
- 0
- in phase 3
- 19
- first study started
- 1997
How studies write it
Studies that test it under each name
Studies by the year they started
50 studies that test it; most in 2011 (8)
| Year | Studies |
|---|---|
| 1997 | 1 |
| 2000 | 2 |
| 2001 | 1 |
| 2002 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 7 |
| 2010 | 4 |
| 2011 | 8 |
| 2012 | 4 |
| 2013 | 5 |
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 1 |
| 2018 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 10
- Phase 3
- 19
- Phase 4
- 19
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 26 · Other 24
Teva Branded Pharmaceutical Products R&D, Inc. (10) · Takeda (4) · H. Lundbeck A/S (4) · Teva Neuroscience, Inc. (3) · University of Florida (2) · Technische Universität Dresden (2) · Bial - Portela C S.A. (2) · Pharma Two B Ltd. (1)
Often tested with
Tested in the same studies.
Pramipexole (2) · Opicapone (2) · Levodopa (1) · Ropinirole (1)
Studies
Open first, then newest update. How each study uses rasagiline is read from its arms, and is right about nine times in ten.
Testing it · 50
- Effect of Rasagiline on Balance in Parkinson's Disease as Measured by Computerized PosturographyWithdrawnPhase 4New York Medical CollegeNCT07077187Written as Rasagiline 1 mg capsule
- Efficacy and Safety of Rasagiline in Prodromal Parkinson's DiseaseWithdrawnPhase 2/3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05611372Written as Rasagiline
- Image Parkinson's Disease Progression StudyCompletedPhase 2University of FloridaNCT02789020Written as Rasagiline
- A Phase 3 Study With P2B001 in Subjects With Early Parkinson'sCompletedPhase 3Pharma Two B Ltd.NCT03329508Written as Rasagiline 0.75 mg
- A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease PatientsCompletedPhase 3TakedaNCT02337725Written as TVP-1012
- A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease ParticipantsCompletedPhase 3TakedaNCT02337764Written as TVP-1012 1mg
- A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease ParticipantsCompletedPhase 2/3TakedaNCT02337738Written as TVP-1012 1mg
- A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease ParticipantsCompletedPhase 3TakedaNCT02337751Written as TVP-1012 1mg
- Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's DiseaseCompletedPhase 4Teva Branded Pharmaceutical Products R&D, Inc.NCT01723228Written as Rasagiline
- Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOnCompletedPhase 4Lundbeck Italia S.p.A.NCT01055379Written as Rasagiline
- Rasagiline Rescue in Alzheimer's Disease Clinical TrialCompletedPhase 2The Cleveland ClinicNCT02359552Written as Rasagiline
- Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 2Richard Barohn, MDNCT01786603Written as Rasagiline
- Rasagiline in the Treatment of Persistent Negative Symptoms of SchizophreniaCompletedPhase 4University of Maryland, BaltimoreNCT00492336Written as rasagiline (Pharmacodynamics)
- Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal DetachmentTerminatedPhase 4Insel Gruppe AG, University Hospital BernNCT02068625Written as Rasagiline
- Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in ChinaCompletedPhase 3H. Lundbeck A/SNCT01479530Written as Azilect®
- Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 2Yunxia Wang, MDNCT01232738Written as rasagiline
- Study of Rasagiline in Patients With Amyotrophic Lateral SclerosisCompletedPhase 2University of UlmNCT01879241Written as Rasagiline
- Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's DiseaseCompletedPhase 4Teva Neuroscience, Inc.NCT01049984Written as Rasagiline
- Effects of Rasagiline on Sleep Disturbances in Parkinson's DiseaseCompletedPhase 4Technische Universität DresdenNCT01442610Written as Rasagiline
- A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic TherapyCompletedPhase 4Georgetown UniversityNCT01497652Written as Rasagiline
See all 50 studies that test rasagiline →
As the comparator · 4 — what is tested is compared with rasagiline
- Relative Bioavailability Study of HNC364 Injectable SuspensionActive, not recruitingPhase 1Guangzhou Henovcom Bioscience Co. Ltd.NCT06798519Written as Rasagiline Tablets
- A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)TerminatedPhase 3Merck Sharp & Dohme LLCNCT01155479Written as Rasagiline 1 mg capsule
- A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)CompletedPhase 3Merck Sharp & Dohme LLCNCT01155466Written as Rasagiline 1 mg capsule
- An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)TerminatedPhase 3Merck Sharp & Dohme LLCNCT01215227Written as Rasagiline
Codes
What other systems call rasagiline · ClinicalTrials.gg INT002968
- MeSH (NLM) C031967rasagilineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 003N66TS6TRASAGILINEConfirmed FDA, NLM, Wikidata
- RxNorm 134748Confirmed FDA, Wikidata
- Wikidata Q420685rasagilineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66510RasagilineOne source FDA
- DrugBank DB01367One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C031967 | rasagiline | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 003N66TS6T | RASAGILINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 134748 | — | Confirmed FDA, Wikidata |
| Wikidata | Q420685 | rasagiline | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66510 | Rasagiline | One source FDA |
| DrugBank | DB01367 | — | One source Wikidata |
Also registered as rasagiline hydrochloride (UNII 2V1ZE3067R) and rasagiline mesylate (UNII LH8C2JI290 · RxNorm 577300).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.